Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MAP1LC3A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP1LC3A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP1LC3A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAP1LC3A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP1LC3A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP1LC3A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006219718 | Prostate | BPH | cellular response to chemical stress | 110/3107 | 337/18723 | 2.44e-13 | 2.40e-11 | 110 |
GO:007149618 | Prostate | BPH | cellular response to external stimulus | 102/3107 | 320/18723 | 8.99e-12 | 6.79e-10 | 102 |
GO:000030218 | Prostate | BPH | response to reactive oxygen species | 76/3107 | 222/18723 | 9.75e-11 | 5.92e-09 | 76 |
GO:004254217 | Prostate | BPH | response to hydrogen peroxide | 56/3107 | 146/18723 | 2.23e-10 | 1.23e-08 | 56 |
GO:003459918 | Prostate | BPH | cellular response to oxidative stress | 90/3107 | 288/18723 | 4.70e-10 | 2.43e-08 | 90 |
GO:003166817 | Prostate | BPH | cellular response to extracellular stimulus | 79/3107 | 246/18723 | 1.32e-09 | 5.69e-08 | 79 |
GO:002241117 | Prostate | BPH | cellular component disassembly | 121/3107 | 443/18723 | 6.34e-09 | 2.25e-07 | 121 |
GO:001003818 | Prostate | BPH | response to metal ion | 104/3107 | 373/18723 | 2.32e-08 | 6.99e-07 | 104 |
GO:00162369 | Prostate | BPH | macroautophagy | 85/3107 | 291/18723 | 4.68e-08 | 1.29e-06 | 85 |
GO:003166910 | Prostate | BPH | cellular response to nutrient levels | 67/3107 | 215/18723 | 8.51e-08 | 2.12e-06 | 67 |
GO:000926710 | Prostate | BPH | cellular response to starvation | 52/3107 | 156/18723 | 2.24e-07 | 4.89e-06 | 52 |
GO:003166718 | Prostate | BPH | response to nutrient levels | 121/3107 | 474/18723 | 3.68e-07 | 7.70e-06 | 121 |
GO:004259410 | Prostate | BPH | response to starvation | 59/3107 | 197/18723 | 2.10e-06 | 3.45e-05 | 59 |
GO:00329849 | Prostate | BPH | protein-containing complex disassembly | 65/3107 | 224/18723 | 2.19e-06 | 3.60e-05 | 65 |
GO:003461417 | Prostate | BPH | cellular response to reactive oxygen species | 49/3107 | 155/18723 | 2.81e-06 | 4.45e-05 | 49 |
GO:00004229 | Prostate | BPH | autophagy of mitochondrion | 30/3107 | 81/18723 | 7.48e-06 | 1.06e-04 | 30 |
GO:00617269 | Prostate | BPH | mitochondrion disassembly | 30/3107 | 81/18723 | 7.48e-06 | 1.06e-04 | 30 |
GO:19030087 | Prostate | BPH | organelle disassembly | 38/3107 | 114/18723 | 9.07e-06 | 1.28e-04 | 38 |
GO:007124110 | Prostate | BPH | cellular response to inorganic substance | 62/3107 | 226/18723 | 2.57e-05 | 3.05e-04 | 62 |
GO:00703016 | Prostate | BPH | cellular response to hydrogen peroxide | 32/3107 | 98/18723 | 7.05e-05 | 6.93e-04 | 32 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501420 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa0502220 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
hsa0513126 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
hsa0421616 | Endometrium | AEH | Ferroptosis | 15/1197 | 41/8465 | 2.83e-04 | 2.30e-03 | 1.68e-03 | 15 |
hsa0413720 | Endometrium | AEH | Mitophagy - animal | 21/1197 | 72/8465 | 7.03e-04 | 4.86e-03 | 3.56e-03 | 21 |
hsa0516725 | Endometrium | AEH | Kaposi sarcoma-associated herpesvirus infection | 44/1197 | 194/8465 | 7.97e-04 | 5.28e-03 | 3.87e-03 | 44 |
hsa05014110 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa05022110 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
hsa05131111 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
hsa0421617 | Endometrium | AEH | Ferroptosis | 15/1197 | 41/8465 | 2.83e-04 | 2.30e-03 | 1.68e-03 | 15 |
hsa04137110 | Endometrium | AEH | Mitophagy - animal | 21/1197 | 72/8465 | 7.03e-04 | 4.86e-03 | 3.56e-03 | 21 |
hsa05167111 | Endometrium | AEH | Kaposi sarcoma-associated herpesvirus infection | 44/1197 | 194/8465 | 7.97e-04 | 5.28e-03 | 3.87e-03 | 44 |
hsa0501425 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
hsa0502225 | Endometrium | EEC | Pathways of neurodegeneration - multiple diseases | 140/1237 | 476/8465 | 9.49e-18 | 2.60e-16 | 1.94e-16 | 140 |
hsa0513127 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
hsa0421625 | Endometrium | EEC | Ferroptosis | 16/1237 | 41/8465 | 1.09e-04 | 1.08e-03 | 8.08e-04 | 16 |
hsa0413725 | Endometrium | EEC | Mitophagy - animal | 22/1237 | 72/8465 | 4.12e-04 | 3.30e-03 | 2.46e-03 | 22 |
hsa0516726 | Endometrium | EEC | Kaposi sarcoma-associated herpesvirus infection | 45/1237 | 194/8465 | 8.55e-04 | 5.86e-03 | 4.37e-03 | 45 |
hsa0501435 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
hsa0502235 | Endometrium | EEC | Pathways of neurodegeneration - multiple diseases | 140/1237 | 476/8465 | 9.49e-18 | 2.60e-16 | 1.94e-16 | 140 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP1LC3A | SNV | Missense_Mutation | | c.218N>A | p.Arg73His | p.R73H | Q9H492 | protein_coding | deleterious(0.01) | probably_damaging(0.927) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
MAP1LC3A | SNV | Missense_Mutation | novel | c.9N>A | p.Met3Ile | p.M3I | Q9H492 | protein_coding | tolerated_low_confidence(0.34) | benign(0) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
MAP1LC3A | SNV | Missense_Mutation | | c.218N>A | p.Arg73His | p.R73H | Q9H492 | protein_coding | deleterious(0.01) | probably_damaging(0.927) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP1LC3A | SNV | Missense_Mutation | | c.118N>A | p.Glu40Lys | p.E40K | Q9H492 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
MAP1LC3A | SNV | Missense_Mutation | | c.239N>T | p.Thr80Met | p.T80M | Q9H492 | protein_coding | deleterious(0) | possibly_damaging(0.689) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD |
MAP1LC3A | SNV | Missense_Mutation | rs753652508 | c.299N>T | p.Ala100Val | p.A100V | Q9H492 | protein_coding | deleterious(0.02) | benign(0.044) | TCGA-CK-5914-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
MAP1LC3A | SNV | Missense_Mutation | | c.196N>A | p.Glu66Lys | p.E66K | Q9H492 | protein_coding | tolerated(0.07) | probably_damaging(0.973) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP1LC3A | SNV | Missense_Mutation | novel | c.23N>A | p.Ser8Tyr | p.S8Y | Q9H492 | protein_coding | tolerated_low_confidence(0.06) | benign(0.001) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MAP1LC3A | SNV | Missense_Mutation | novel | c.367T>C | p.Phe123Leu | p.F123L | Q9H492 | protein_coding | tolerated(0.05) | possibly_damaging(0.631) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP1LC3A | SNV | Missense_Mutation | novel | c.371G>A | p.Gly124Asp | p.G124D | Q9H492 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |